Noble Life Sciences Animal Facility Awarded Full AAALAC Accreditation
News Nov 01, 2013
Noble Life Sciences has announced that its animal facility was awarded full accreditation by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC International).
AAALAC assessment and accreditation programs are designed to recognize organizations that demonstrate excellence in animal care and use.
Organizations volunteer to participate in AAALAC's program in addition to complying with local, state and federal laws that regulate use of animals in research.
Accreditation was awarded following submission of a detailed program description and an in-depth review of the program and facility during an on-site visit by AAALAC representatives.
In addition, Noble is currently licensed by the United States Department Of Agriculture (USDA) and meets the assurance requirements of the National Institutes of Health’s Office of Laboratory Animal Welfare (OLAW).
Alain Cappeluti, President of Noble Life Sciences, commented: “We are pleased to receive unanimous approval from AAALAC International for full accreditation with no additional recommendations for improvement. Accreditation recognizes our commitment to exceed international standards with the highest level of animal care and research practices. It also demonstrates our dedication to providing our clients with superior resources and services to advance their preclinical research programs.”
Fermentation Byproduct Suppresses Seizures in Nerve Agent PoisoningNews
A compound found in trace amounts in alcoholic beverages is more effective at combating seizures in rats exposed to an organophosphate nerve agent than the current recommended treatment.READ MORE
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE